Skip to main content
. Author manuscript; available in PMC: 2006 Jul 1.
Published in final edited form as: Cancer Gene Ther. 2006 Jan 1;13(1):82–90. doi: 10.1038/sj.cgt.7700863

Fig. 4.

Fig. 4

Suppression of 4T1 tumor growth in vivo. Subcutaneous tumors derived from the 4T1 cells were treated with various reagents as indicated. Tumor volumes were monitored over time after the treatments. The values represented the means ± the standard error of 12 mice per group. The mean tumor volume in the animals treated with Ad/TRAIL-F/RGD or Delta24 alone differed significantly from that of Ad/CMV-GFP treated group (P <0.05). Treatment with Ad/TRAIL-F/RGD plus Delta24 differed significantly from all other treatment groups (P <0.05).